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Abstract
Aims/hypothesis Womenwith a history of gestational diabetes
mellitus (GDM) have raised liver triacylglycerol. Restriction
of energy intake in type 2 diabetes can normalise glucose
control and liver triacylglycerol concentration but it is not
known whether similar benefits could be achieved in GDM.
The aim of this work was to examine liver triacylglycerol
accumulation in women with GDM and the effect of modest
energy restriction.
Methods Sixteen women with GDM followed a 4 week diet
(5 MJ [1200 kcal]/day). Liver triacylglycerol, before and after
diet and postpartum, was measured by magnetic resonance.
Insulin secretion and sensitivity were assessed before and after
diet. Twenty-six women who underwent standard antenatal
care for GDM (matched for age, BMI, parity and ethnicity)
were used as a comparator group.
Results Fourteen women, who completed the study, achieved
a weight loss of 1.6±1.7 kg over the 4 week dietary period.
Mean weight change was −0.4 kg/week in the study group vs
+0.3 kg/week in the comparator group (p=0.002). Liver tri-
acylglycerol level was normal but decreased following diet
(3.7% [interquartile range, IQR 1.2–6.1%] vs 1.8% [IQR
0.7–3.1%], p=0.004). There was no change in insulin sensi-
tivity or production. Insulin was required in six comparator
women vs none in the study group (eight vs two required
metformin). Blood glucose control was similar for both
groups. The hypo-energetic diet was well accepted.
Conclusions/interpretation Liver triacylglycerol in women
with GDM was not elevated, unlike observations in non-
pregnant women with a history of GDM. A 4 week hypo-
energetic diet resulted in weight loss, reduced liver triacyl-
glycerol and minimised pharmacotherapy. The underlying
pathophysiology of glucose metabolism appeared unchanged.
Keywords Gestational diabetes . Insulin resistance .
Intrahepatic lipid . Magnetic resonance spectroscopy .
Pregnancy
Abbreviations
ALT Alanine aminotransferase
GDM Gestational diabetes mellitus
IQR Interquartile range
MFP MyFitness Pal
MRS Magnetic resonance spectroscopy
Introduction
Gestational diabetes mellitus (GDM) is recognised to be an
early manifestation of type 2 diabetes mellitus, with shared
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pathogenic features [1]. Recently, it has been demonstrated
that individuals with type 2 diabetes can durably be returned
to non-diabetic glucose control by substantial weight loss de-
pending on initial reduction in liver triacylglycerol content [2,
3]. However, information on liver triacylglycerol content in
GDM is limited even in animal models [4].
In type 2 diabetes, both liver triacylglycerol and fasting
plasma glucose are normalised within 7 days of a substantial
reduction in energy intake [5]. Over a period of weeks, a more
moderate reduction of energy intake to 5 MJ (1200 kcal)/day
decreases liver triacylglycerol content and plasma glucose [6].
High levels of liver triacylglycerol are known to be present
years before the diagnosis of type 2 diabetes [7] and women
with previous GDM have markedly elevated liver triacylglyc-
erol levels [8, 9]. As normal pregnancy is associated with a
greater than twofold increase in plasma triacylglycerol levels
[10], a physiological rise in liver triacylglycerol would be
expected during pregnancy as these variables are usually
closely associated [11]. This may be exaggerated in pregnan-
cies complicated by GDM.
Food restriction in pregnancy, as a way to improve
adverse metabolic factors, understandably raises concerns.
Many of these concerns are unfounded [12] and, conversely,
both obesity and gestational diabetes are known to confer
substantial risks [13, 14]. Meta-analysis has shown that
weight loss in pregnancy in healthy women reduces the inci-
dence of GDM and also pre-eclampsia, gestational hyperten-
sion and preterm birth, with no effect on fetal growth [15].
However, current guidelines do not recommend weight loss
during pregnancy [16]. Further, there is little information on
how accepting womenwith GDMwould be towards receiving
specific advice to decrease energy intake.
The primary aims of this study were to define the extent of
liver triacylglycerol accumulation during pregnancy in wom-
en diagnosed with GDM and the effect upon this of modest
energy restriction. The metabolic effects and acceptability of
energy restriction in GDM were also examined.
Methods
Study population Between January 2015 and August
2015, 16 women between 21 weeks and 34 weeks gesta-
tion (mean 27 ± 3.3 weeks) with a singleton pregnancy
were recruited from the antenatal clinic at the Royal
Victoria Infirmary, Newcastle upon Tyne following a pos-
itive 75 g OGTT (fasting glucose ≥5.5 mmol/l, 2 h glucose
≥7.8 mmol/l) [17]. In accordance with National Institute
for Health and Care Excellence (NICE) guidelines the
presence of one or more of the following necessitated an
OGTT [18]: BMI above 30 kg/m2, previous baby
weighing more than 4.5 kg, previous GDM, family history
of diabetes and ethnic minority with a high prevalence of
diabetes. Women with multiple pregnancy or contraindi-
cation to magnetic resonance scanning (ferromagnetic im-
plant, claustrophobia, abdominal circumference >102 cm)
were excluded. To compare weight change and pregnancy
outcomes, each participant was matched with the two best
comparators with GDM available from the Caldicott approved
hospital maternity database according to age (within ±5 years,
mean difference 0.5±3.3 years), BMI (within ±6 kg/m2, mean
difference 1.2±2.9 kg/m2), parity (nulliparous or multiparous)
and ethnic origin. Data regarding weight change, fetal growth,
home blood glucose monitoring and treatment were obtained
for the matched participants over a similar 4 week gestational
window. The study participants and the comparators were
both identified by initial screening followed by a positive
OGTT using the above criteria. The comparator group were
reviewed once by a dietitian, given a dietary information leaf-
let and were taught how to carry out home blood glucose
monitoring; glycaemic control was overseen by a diabetes
specialist midwife.
The Wellbabe (Weight Loss Looking for Baby and
Mother’s Better Outcomes) study was approved by the
Newcastle and North Tyneside Ethics Committee (14/NE/
1085) and all women gave written informed consent. The
study was registered with the ISRCTN (http://isrctn.org
17505466).
ProtocolWomen were invited to participate at the first clinic
visit after diagnosis of GDM. A magnetic resonance spectros-
copy (MRS) scan and standardised meal test were performed
before and after the 4 week hypo-energetic diet. Fetal growth
scans, measuring abdominal circumference [19], were con-
ducted at 28, 32 and 36 weeks’ gestation and data regarding
weight and home blood glucose monitoring were collected. In
the light of data obtained, further ethical permission was ob-
tained to carry out postpartum liver triacylglycerol measure-
ments and fasting blood tests between 12 weeks and 28 weeks
after delivery.
Dietary intervention The 5 MJ (1200 kcal)/day diet (50%
carbohydrate, 25% protein, 25% fat) was designed to limit
energy intake while ensuring nutritional adequacy (food por-
tion plan plus calcium-containing pregnancy multivitamins)
during pregnancy. Specific dietary advice was provided dur-
ing a face-to-face consultation, delivered by trained team
members, following the standardised meal test at the first visit
to the clinic. The rationale for the diet was explained and
motivation, facilitators and barriers to implementation of the
dietary changes were explored. The diet portion plan was ex-
plained in full and a supporting booklet was provided (see
electronic supplementary material [ESM]) along with a sam-
ple 7 day meal plan and suggested recipes. Each participant’s
usual energy intake was reviewed and modified to match the
5 MJ (1200 kcal) portion plan. Where necessary the portion
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plan was changed to reflect an individual’s food preferences.
A portion cup was provided to measure appropriate amounts
of breakfast cereals, rice and pasta. MyFitnessPal (MFP)
(Under Armour, Baltimore, MD, USA), a smartphone applica-
tion, was used to record dietary intake. Women consented to
sharing their dietary and glycaemic control data with the re-
search team (KH and AB) so that progress could be monitored
daily and support and advice given via MFP messaging or
telephone call accordingly (based on MFP data assessment by
the study team). Targets for home blood glucose monitoring
were fasting glucose <5.5 mmol/l and 1 h postprandial glucose
<7.8 mmol/l. Metformin and/or insulin were started if glucose
levels were persistently above target. Following completion of
the 4 week dietary plan, KH provided a revised portion plan for
the remainder of the pregnancy. In most cases the women were
advised to avoid weight gain and to continue on ∼1500 kcal/
day, although this was individualised according to weight loss
and glycaemic control.
Magnetic resonance protocol Studies were performed using
a Philips 3 Tesla Achieva whole-body scanner (Philips
Medical Systems, Best, the Netherlands) using a Philips
multi-channel flex coil for 1H imaging and spectroscopy. To
avoid pressure on the inferior vena cava, participants were
positioned with a left pelvic tilt. Scout images of the maternal
abdomen were acquired to guide identification of the volume
of interest within the liver. 1H spectroscopy comprised acqui-
sition of point resolved spectroscopy-localised spectra at six
echo times (repetition time=2.8 s; echo time=36, 50, 75, 100,
125 and 150 ms; spectral width=2 kHz; 2000 data points)
from a 3 cm×3 cm×3 cm voxel positioned in the liver to
avoid large vessels.
Spectra were processed using the Java-based magnetic res-
onance user interface (jMRUI version 3.0) [20, 21] and peak
areas were determined using the AMARES non-linear least
square fitting algorithm [22]. Resonances of water at 4.7 ppm
and the CH2 methylene peak at 1.3 ppm in
1H spectra were
quantified. The mean spin–spin relaxation time (T2) was de-
termined for each peak by fitting a mono-exponential to the
data. Signal amplitude at an effective echo time of zero was
determined, and the amplitude used to obtain the liver triacyl-
glycerol fraction value. The percentage of triacylglycerol was
calculated from the ratio of signal amplitude triacylglycerol
divided by total signal amplitude from water plus triacylglyc-
erol× 100. The upper limit of normal for a US population of
mixed-sex, multi-ethnic participants aged 30–65 years has
been defined as 5.5% [23].
Liver triacylglycerol content was assessed at baseline and
after the 4 week hypo-energetic diet. Participants continued on
the diet until the second visit to the clinic.
Standardised meal test Prior to metabolic testing, women
were asked to avoid vigorous exercise and to fast overnight.
Participants were transported to and from the Newcastle
Magnetic Resonance Centre by taxi. A standardised breakfast
was eaten over 10–15 min (two Weetabix [wholewheat cereal
biscuits], 200 ml semi-skimmed milk, 200 ml orange juice, a
white bread roll, 20 g strawberry jam and 10 g margarine,
totalling 2.4 MJ [575 kcal; 72% carbohydrate, 15% protein,
13% fat]). Blood samples for measurement of glucose, insulin
and C-peptide were taken via an intravenous cannula at 0, 10,
20, 30, 60, 90,120 and 180min. HbA1c, lipids (triacylglycerol,
total cholesterol, HDL-cholesterol and LDL-cholesterol),
fasting NEFA and urea and electrolytes were measured and liver
function tests and full blood count were performed [24, 25]. The
participants were sitting comfortably during the meal test, with
intermittent brief walking as desired. The meal test was carried
out at baseline and at the end of the hypo-energetic diet.
Insulin sensitivity in the fasted state was calculated from
fasting glucose and insulin concentrations using the HOMA2
index (available from www.dtu.ox.ac.uk/homacalculator/,
accessed 21 June 2016 [26].) The oral glucose minimal model
was used to analyse insulin sensitivity (SI) during the meal [24,
25]. Beta cell insulin secretion was calculated from the oral C-
peptide minimal model [24, 25].
Home blood glucose monitoringWomen were supplied with
a Bayer Contour meter (Basel, Switzerland). They were asked
to measure glucose levels daily before breakfast (fasting) and
1 h after their main meal. Data were relayed to KH daily either
through MFP or by telephone. The need for metformin and/or
insulin was assessed as part of routine management.
Qualitative studyA semi-structured interviewwas conducted
with each participant by an independent research midwife
(CM) who was experienced in qualitative methodology. An
interview schedule was developed using the Theory Domain
Framework [27] to explore motivation to engage in the diet,
beliefs about consequences and emotions (e.g. fears) among
other domains. The full qualitative study analysis will
be published separately.
Statistics Data were analysed in SPSS V21.0 (IBM, Armonk,
NY, USA). Continuous variables are expressed as mean±SD.
Continuous data were compared using the two-tailed paired
Student’s t test and ANOVAwhen there were multiple groups.
Non-parametric continuous data were compared using
Wilcoxon’s signed-rank test. Significance was set at p<0.05.
A power calculation was undertaken based upon change in
liver triacylglycerol. This was based on a previous study from
our institution in participants with type 2 diabetes as there
were no published data on liver triacylglycerol in human preg-
nancy [5]. In our previous study liver triacylglycerol fell from
12.8±2.4% to 4.8±4.2% over a 4 week period. Given that the
degree of energy restriction in the present study was 60% less
than in the previous study, and that fall in liver triacylglycerol
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is proportionate to reduction in energy intake, we assumed
that the reduction in liver triacylglycerol would be 60% of that
previously reported. Thirteen participants would be required
to demonstrate an absolute fall in liver triacylglycerol of 4.8%
(assuming SD of 4.2 and baseline level of 12%) with 95%
power at the 5% significance level.
Results
Patient demographics Sixteen women were recruited. Two
women dropped out (during weeks 1 and 2) citing pressure of
time and social circumstances. One participant was unable to
undergo magnetic resonance (claustrophobia) but underwent
all other aspects of the protocol. To compare the clinical effect
of the hypo-energetic diet with that of standard management,
matched comparators with GDM were identified from the
maternity database (n=28; complete data available on 26)
(Table 1).
Weight changeDuring the hypo-energetic diet, participants
lost a mean of 0.4 ± 0.4 kg per week during the intervention
compared with a weight gain of 0.3 ± 0.3 kg per week in
the comparator group (p< 0.001). The total weight loss in
participants was 1.6±1.7 kg compared with a total gain of 1.4
±1.2 kg in comparators. Six participants lost more than 2 kg
(2.1–5.6 kg), five lost 0.3–1.2 kg and three participants put on
weight (0.2–0.5 kg).
Liver triacylglycerol Before dietary intervention, at gestational
age 21–34 weeks, median liver triacylglycerol was 3.7%
(interquartile range [IQR] 1.2–6.1%). After 4 weeks of
dietary intervention the median liver triacylglycerol was
approximately halved to 1.8% (IQR 0.7–3.1%; p= 0.004).
Individual data are shown in Fig. 1. One woman had very
high pre-diet liver triacylglycerol levels (>20%); repeat
analysis excluding this individual did not change the
statistical significance (3.4% [IQR 1.1–4.1%] pre-diet,
1.4% [IQR 0.7–2.9%] post-diet; p= 0.006).
Measurement of liver triacylglycerol was repeated at
12–28 weeks postpartum; median levels were similar to
those seen pre-diet (pre-diet 3.7% [IQR 1.2–6.1%], post-
partum 3.5% [IQR 2.0–3.7%], p= 0.81).
Standardised meal test Fasting plasma glucose remained
unchanged after the dietary period (4.3 ± 0.5 mmol/l vs
4.4 ± 0.7 mmol/l, p= 0.49). The HOMA2 index was similar
before and after dietary intervention (1.3 ± 0.4 vs 1.4 ± 0.4,
p = 0.47) and was lower postnatally (0.6 ± 0.2, p < 0.01).
The postprandial glucose concentration curve was similar
before and after dietary intervention. Glucose peaked at
60 min at a concentration of 8.2 ± 1.0 mmol/l before the diet
and 8.4 ± 1.5 mmol/l after the diet. There was no statistically
significant difference between fasting insulin or C-peptide before
and after the diet (38±19 vs 48±23 pmol/l insulin, respectively,
p=0.12; 0.61±0.19 vs 0.65±0.10 nmol/l C-peptide, respective-
ly, p=0.36). Acute insulin secretion did not change during the
standard meal test after the diet (Φtotal 62±18 vs 58±12 [×10
−9]/
min, p=0.52). Insulin concentrations peaked at 60 min (493
± 148 pmol/l before diet vs 513 ± 239 pmol/l after diet,
p=0.69). C-peptide levels peaked at 90 min before diet (3.0
±0.9 nmol/l) and at 120 min after the diet (3.7±0.9 nmol/l).
There was no change in post-meal SI before and after diet
(14.3 ± 6.0 vs 13.4 ± 7.6 × 10−5 dl kg−1 min−1 [pmol/l]−1,
p=0.55).
Lipid profile Lipid profiles before and after diet and during
the postnatal period are shown in Fig. 2. The pregnancy-
associated increase in plasma triacylglycerol was unchanged
by the hypo-energetic diet. Similarly, there was no difference
in HDL-cholesterol and non-HDL-cholesterol levels before
Table 1 Baseline characteristics of participant and comparator groups
Characteristic Participants
(N= 14)
Controls
(N= 26)
Age (years) 31.5 ± 4.6 30.9 ± 4.4
Weight (kg) 93.1 ± 13.9 90.5 ± 17.1
Height (cm) 164 ± 6.3 163 ± 5.8
BMI (kg/m2) 34.6 ± 4.1 34.1 ± 6.1
Nulliparous 8 (57) 15 (58)
History of GDM/type 2 diabetes 12 (86) N/A
OGTT (mmol/l)
0 min 5.0 ± 0.8 5.1 ± 1.0
120 min 8.5 ± 0.6 8.9 ± 1.8
Data are shown as means ± SD or n (%)
All participants and controls were of white British ethnicity
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Fig. 1 Percentage liver triacylglycerol before and after dietary interven-
tion (n = 13) and postpartum (n= 7). Circles show individual values; bars
show the median. p = 0.004 before vs after intervention
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and after the diet. Mean triacylglycerol and total cholesterol
levels fell after delivery (p<0.05 for both).
NEFA There was no significant difference in fasting NEFA
before and after intervention (0.42±0.21 vs 0.48±0.25mmol/
l; p=0.18).
Liver function testsMedian alanine aminotransferase (ALT)
was 18 U/l (IQR 14–25 U/l) before dietary intervention and
24U/l (IQR 20–32U/l) after. Two participants had an elevated
ALT (62 and 93 U/l) pre-diet and one had an ALT that rose
from 26 U/l before intervention to 83 U/l following the diet.
The womenwith elevated ALT had negative investigations for
viral hepatitis. In these two participants ALT was monitored
throughout pregnancy and returned to normal limits after
delivery.
Glucose control None of the hypo-energetic diet group
required insulin therapy compared with six of the 26
women in the comparator arm. Two participants in the
diet group required metformin therapy (weight loss
0.3 kg and 1.2 kg) compared with eight of the compar-
ators, six women requiring both metformin and insulin
in the comparator population.
Despite the pharmacotherapy, home monitoring during the
4 week intervention period showed similar mean blood glu-
cose levels for the diet and comparator groups respectively
(fasting 4.9± 0.6 vs 4.9± 1.0 mmol/l; postprandial 6.6± 0.8
vs 6.6±0.9 mmol/l). MeanHbA1c did not differ between groups
(5.2±0.6% [34±4 mmol/mol] vs 5.3±0.8% [34±5 mmol/mol]
for the diet and comparator groups respectively, p=0.89).
Maternal and fetal outcomes All women in the dietary
intervention group expressed positive thoughts about the
experience of decreasing energy intake during pregnancy.
There was no difference in mode of delivery between
participants and comparators. None of the women had
shoulder dystocia or a third-degree tear. No difference in
the rate of increase in fetal abdominal circumference was
observed when comparing the diet and comparator groups
(ESM Fig. 1). There was no difference in birthweight
between participant and comparator groups (Table 2).
One baby in the study group was admitted to the
special-care baby unit for chylothorax, detected at
36 weeks’ gestation. Excluding this baby, APGAR scores
ranged from 7 to 9 at 1 min and from 9 to 10 at 5 min. No
babies had neonatal hypoglycaemia.
Discussion
The present study suggests that GDM is not typically
characterised by high levels of liver triacylglycerol. The
hypo-energetic diet brought about a weight loss of 0.4 kg/
week and halved liver triacylglycerol content. Over the 4 week
treatment period there was no change in insulin secretion in
response to a test meal. The diet was well tolerated, resulting
in glycaemic control equivalent to that achieved using con-
ventional management (insulin and metformin as required).
The observation of normal liver triacylglycerol levels did not
match the expectation arising from analysis of the literature.
Previous studies have demonstrated that non-pregnant women
with a history of GDM have elevated liver triacylglycerol levels
[8, 9] and have a greater risk of non-alcoholic fatty liver disease
in later life [28]. Given that excess intrahepatic triacylglycerol is
an important underlying factor in the development of type 2
diabetes, with average levels of 12.8±2.4% [3, 7], it was antic-
ipated that increased fat would be observed in women with
newly diagnosed GDM. Further, raised liver triacylglycerol
levels in type 2 diabetes are associated with raised plasma
triacylglycerol [29], and plasma triacylglycerol levels are
increased to a greater extent in GDM than in non-diabetic
pregnancy [29]. Abnormal lipid metabolism appears to
have a central role in GDM [10]. The present data are the
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Fig. 2 Plasma cholesterol and triacylglycerol lipoproteins inwomenwith
GDM before (light grey bars) and after (dark grey bars) dietary interven-
tion (n= 14) and postpartum (black bars) (n = 7). Data are means ± SD.
*p< 0.05 before diet vs postpartum
Table 2 Maternal and fetal outcomes
Outcome Participants
(N= 14)
Controls
(N = 26)
p value
Mean gestation at delivery (weeks) 38 38
Spontaneous vaginal delivery 6 (54%) 10 (38%)
Instrumental delivery 1 (10%) 5 (19%)
Elective Caesarean section 2 (18%) 6 (23%)
Emergency Caesarean section 2 (18%) 5 (19%)
Birthweight (g) 3360 ± 277 3361± 398 0.99
Average birthweight (centile) 54 ± 26 52± 25 0.84
SCBU admission 1 2
Data are shown as means ± SD, n or n (%)
SCBU, special-care baby unit
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first in vivo magnetic resonance liver triacylglycerol
measurements to be reported during human pregnancy.
The observation of apparently normal liver triacylglycerol
content in most participants raises the possibility that liver
triacylglycerol content may decrease during pregnancy despite
increases in plasma triacylglycerol, and that levels which are
normal in the non-pregnant state may be associated with
GDM. It is interesting to note that liver triacylglycerol, but
not plasma triacylglycerol, decreased following hypo-
energetic dieting. This is likely to reflect the physiological
adaptation of pregnancy, with requirement for a sharp increase
in plasma triacylglycerol after the first trimester, and change in
nutritional state is unlikely to change this.
The present data raise the possibility that liver fat levels fall
reciprocally with elevation of plasma triacylglycerol. This
hypothesis can be tested in a future study. It is consistent with
ultrasound findings of an association between the presence of
liver steatosis in early pregnancy and the subsequent risk of
GDM [30] and also the association of raised ALTwith risk of
GDM [31]. However, in the aforementioned study, liver
ultrasound was performed between 11 and 14 weeks, before
the onset of either raised plasma triacylglycerol or significant
insulin resistance. In the present study we did not observe any
marked change in liver triacylglycerol after pregnancy,
although it is not known how long any pregnancy-associated
change in liver triacylglycerol may take to return to non-
pregnancy levels. Now that the safety of MRS in pregnancy
is accepted, further work is required to establish the physiol-
ogy of liver triacylglycerol in non-diabetic pregnancy and to
compare differences in GDM. To our knowledge, there are no
quantitative studies of human or animal liver fat during
normal pregnancy. It is established that a very-high-fructose
diet during pregnancy is associated with histologically
assessed steatosis in animal models [4].
The study group were representative of the wider popula-
tion of women with GDM.Age and BMI were similar to those
of participants in larger studies of GDM [14, 32]. HbA1c in the
study group (5.3± 0.4% [34±4 mmol/mol]) was similar to
that at the time of diagnosis in all women recorded in the
Newcastle GDM database (5.5 ± 0.8% [36± 9 mmol/mol]).
The group was predominantly white British, reflecting the
population of the North East of England.
The time course of return of normal first-phase insulin
secretion for people with type 2 diabetes during a very-
low-energy diet has been defined [5]. Even at 2.5–3.3 MJ
(600–800 kcal)/day, 8 weeks was required for normal in-
sulin secretion to be restored and at 4 weeks improvement
was modest. The present study necessarily used a less
severely restricted diet of 5 MJ (1200 kcal)/day and, as
a first step, this was advised for 4 weeks only. The lack of
change in insulin secretion following the test meal is
therefore not unexpected. Further work is required to es-
tablish whether the insulin secretory abnormality in GDM
[33], being of short duration, is more readily reversed
than that of type 2 diabetes.
Dietary weight loss during pregnancy is viewed with cau-
tion bymany obstetricians, even though obesity is a major risk
factor for macrosomia and associated adverse outcomes. The
benefits of minimising weight gain during pregnancy, in the
present era of steady weight gain during adult life, were first
reported several years ago [34]. This is especially relevant in
GDM [14, 32, 35]. A clear decrease in energy intake has been
achieved on a whole-clinic basis by Asbjornsdottir and col-
leagues who achieved a decrease in median weight gain dur-
ing pregnancy from 12.1 to 3.7 kg [36]. This was associated
with decreases in large-for-gestational-age infants (39% to
12%) and perinatal morbidity (71% to 35%). At the time when
GDM is diagnosed there is likely to be increasedmotivation to
decrease energy intake. All 14 women who completed the
study reported that they were comfortable with the explana-
tion of likely benefit for their baby. The present study is
unique in demonstrating the effectiveness and acceptability
of modest weight loss at the time of diagnosis of GDM. A
randomised study of dietary weight loss is now required.
Several practical features of the dietary intervention merit
discussion. The reasons why weight loss in pregnancy was be-
lieved to be important for fetal health were carefully explained
to each woman. Diets were individualised according to pre-
ferred eating habits and women were asked to discuss this with
family and friends. The use of current smartphone technology
encouraged engagement with the diet and regular communica-
tion with the study team. Women reported that this immediacy
of communication facilitated dietary compliance and allowed
access to medical advice for management of their blood glucose
levels. The dietary intervention was more intensive than con-
ventional intermittent clinic review, although halving of gesta-
tional weight gain has previously been reported using monthly
dietetic consultations [37].
The number of women studied was small, but the partici-
pants were representative of the wider population with GDM.
The study was large enough to demonstrate a highly statisti-
cally significant difference in weight loss between interven-
tion and comparator groups. However, due to the small sample
size it was not possible to adjust for other factors that may
differ between the groups, nor was it possible to subanalyse
the group (for example, to study the outcome of those who lost
more weight than others). As women were advised of the
diagnosis of GDM and of the aims of the study at a clinic visit
several days before the baseline measurements, the baseline
necessarily reflects an initial dietary intervention (mean
fasting glucose falling from 5.0 mmol/l to 4.3 mmol/l).
Avoidance of insulin therapy is associated with major benefit
in simplifying peripartum obstetric management as well as
minimising weight gain, personal inconvenience and use of
healthcare resources. Even so, most women were in the lower
range of plasma glucose concentration for diagnosis of GDM
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and it will be important to study women with higher presenting
blood glucose levels. Size restrictions within the magnetic
resonance scanner preclude women with an abdominal
circumference greater than 102 cm from taking part in such
studies. However, no woman in this study was excluded on
this criterion.Womenwith the highest BMImight be expected
to have the strongest association between GDM and hepatic
steatosis and to experience a more dramatic effect of energy
restriction on the liver. However, recent data on the lack of
association between raised ALT and risk of GDM in more
obese women suggest that this is unlikely [31].
The present study highlights the important question of liver
triacylglycerol physiology in normal and GDM pregnancy
and provides data for informing the design of further studies.
Additionally, there is a need for a prospective randomised
therapeutic study of dietary weight loss from the time of
diagnosis of GDM.
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